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COST-EFFECTIVENESS STUDIES
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OBJECTIVES: Recent evidences have shown that glucosamine sulphate (GS) is a 
potentially effective treatment for osteoarthritis; however, it is unclear whether its use 
is cost-effective from the perspective of Thai Ministry of Public Health (MOPH). This 
study aims to estimate the cost-effectiveness of glucosamine sulphate (GS) compared 
with current care (CC) in osteoarthritis (OA) patients in Thailand. METHODS: A 
Markov model was used to simulate 10,000 hypothetical OA cohorts. The model 
comprised four health states including OA without total knee replacement (TKR), OA 
with TKR, OA after TKR, and death. Transition probabilities and health state utilities 
were obtained from published literature. Drug cost was obtained from the Drugs and 
Medical Supplies Information Center, MOPH, while the cost of TKR was based on 
the reimbursement rate provided by National Health Security Ofﬁ ce. The model 
estimated quality-adjusted life-years (QALYs), costs and incremental cost-effectiveness 
ratio (Cost/QALY gained) over life time horizon. Probabilistic sensitivity analyses 
(PSA) were undertaken. Both cost and health outcomes were discounted at 3%. 
RESULTS: The estimated QALYs were 17.88 and 17.79 QALYs for GS and CC, 
respectively. The lifetime direct medical costs for GS (generic brand), GS (original 
brand) and CC were 123,679 THB, 279,988 THB, and 57,863 THB, respectively. 
Compared to CC, the incremental cost per QALYs gained was 774,125 THB/QALY 
for GS generic brand and 2,612,605 THB/QALY for GS original brand. Based on a 
cost-effectiveness cut-off of 100,000 and 300,000 THB/QALY, the probability that 
GS (generic brand) being cost-effective was 38.6% and 50.0%, respectively. Using GS 
generic brand would be cost-effective if the GS price is lowered about two-thirds of 
the current price. CONCLUSIONS: Using GS in OA patients may not be cost-effective 
from the perspective of Thai Ministry of Public Health. Policymakers may consider 
using such value for money information for aiding policy decision-making. 
CE2
COST-UTILITY ANALYSIS OF INTENSIVE LIFESTYLE INTERVENTIONS 
OR METFORMIN VERSUS STANDARD CARE IN THE PREVENTION OF 
TYPE 2 DIABETES IN HIGH-RISK SUBJECTS IN AN AUSTRALIAN 
SETTING. A SIMULATION ANALYSIS BASED ON THE LONG-TERM 
RESULTS OF THE DIABETES PREVENTION PROGRAM AND DIABETES 
PREVENTION PROGRAM OUTCOMES STUDY
Tucker DM, Palmer AJ
Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia
OBJECTIVES: The 3-year Diabetes Prevention Program (DPP) and 7-year follow-up 
Diabetes Prevention Program Outcomes Study (DPPOS) demonstrated that both inten-
sive lifestyle interventions (ILI) and metformin led to reductions in the incidence of 
type 2 diabetes (T2D) versus standard care (control) in overweight or obese subjects 
with impaired glucose tolerance (IGT). Our aim was to project the long-term cost-
utility of T2D prevention in an Australian setting, based on clinical results and 
resource utilization from the DPP + DPPOS. METHODS: We developed a semi-
Markov, second-order Monte Carlo model to project the 10-year clinical and cost 
results of the DPP + DPPOS to patient lifetimes. Four health states were modeled: 
normoglycemia (NG); IGT; T2D and dead. Subjects started in IGT and progressed to 
T2D or NG, depending on the treatment received. State-speciﬁ c mortality rates for 
NG, IGT, or T2D were used. We incorporated direct medical costs (from ofﬁ cial 
Australian published sources and the reimbursement perspective) and Australian 
utility and probability data. Total lifetime costs (C), quality-adjusted life-years 
(QALY) and incremental C/QALY-gained were calculated for ILI or metformin versus 
control. Outcomes were discounted at 5% annually. Validations and sensitivity analy-
ses were performed. RESULTS: Delayed onset of T2D led to mean (standard devia-
tion) QALY-gained of 0.38 (0.05) and 0.12 (0.04) years for ILI or metformin versus 
control, respectively. Costs savings of $282 (4222) per patient and cost increases of 
$1116 (4338) were projected for ILI or metformin versus control, respectively. ILI 
was dominant to control. C/QALY-gained for metformin versus control were $8757. 
Probability of acceptance at a willingness to pay threshold of $50,000 were 100% 
and 85% for ILI or metformin respectively. Results were most sensitive to probabilities 
of developing T2D, and costs of implementing the interventions. CONCLUSIONS: 
Lifetime projection of the DPP + DPPOS results found ILI dominant and metformin 
to be cost-effective versus control by current Australian standards. 
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OBJECTIVES: To evaluate the cost-utility of cholinesterase inhibitors (i.e., donepezil, 
rivastigmine, and galantamine) compared with no drug treatment in patients with mild 
to moderate Alzheimer’s disease (AD) based on the governmental and societal perspec-
tives and to estimate the budget impact when providing the cost-effective treatment. 
METHODS: A Markov model was used to evaluate the cost-utility of drug treatment 
options versus no drug treatment. Input parameters on the clinical efﬁ cacy of cholin-
esterase inhibitors were obtained from systematic reviews and meta-analysis of inter-
national literature. The costs associated with AD were obtained from primary data 
collection at a university hospital and literature reviews. All costs were presented in 
2008 Thai (THB). Probabilistic sensitivity analysis was performed to assess uncer-
tainty surrounding model parameters. RESULTS: Based on both governmental and 
societal perspectives, galantamine was the most cost-effective compared with other 
drugs and no treatment option. The ICER at the base case scenario (i.e., patients with 
60-year-old who had AD disease for 1 year, an Alzheimer Disease Assessment Scale-
Cognitive (ADAS-cog) score of 17, no presence of psychotic and extra-pyramidal 
symptoms (EPS) was 229,367 THB and 157,247 THB per QALY gained using the 
governmental and societal perspectives, respectively. Moreover, when providing galan-
tamine for patients with EPS or patients with ADAS-cog score ranging from17 to 30 
or patients having psychotic symptoms, galantamine was still more cost-effective 
compared with the base case scenario. Furthermore, the additional budgets required 
for providing galantamine for all Thai patients with mild to moderate AD at the ﬁ rst 
year were 12,768 million THB. CONCLUSIONS: At the ceiling threshold of three 
times of gross domestic product (GDP) per capita (300,000 Baht per QALY), provid-
ing galantamine would be a cost-effective intervention for mild to moderate AD 
patients in Thailand. Galatamine would also be cost-effective at the threshold of one-
time of GDP per capita (100,000 Baht per QALY) for patients with EPS. 
CE4
ECONOMIC EVALUATION OF REHABILITATION SERVICES FOR 
INPATIENT WITH STROKE IN TWO REGIONAL HOSPITALS IN THAI 
CONTEXT
Khiaocharoen O1, Teerawattananon Y2, Pannarunothai S3, Riewpaiboon W4
1Naresuan University Faculty of Medicine, Pitsanuloke, Thailand; 2Health Intervention and 
Technology Assessment Program (HITAP), Nonthaburi, Thailand; 3Naresuan University, Muang, 
Phitsanulok, Thailand; 4The Program of Health Promotion for People with Disabilities in Thai 
Society, Nonthaburi, Thailand
OBJECTIVES: To evaluate cost-effectiveness and cost-utility of rehabilitation for 
stroke patients under Thai settings. METHODS: This was a prospective observational 
cohort study with a 4-month follow-up. Subjects were 207 ﬁ rst stroke patients in two 
regional hospitals. Data was prospectively collected from July 2008 to May 2009. 
Top-down and bottom-up costing approaches were employed using societal perspec-
tive. The Barthel index (BI) was used to evaluate functional status and the EQ-5D was 
used to assess patients’ quality of life. Effectiveness was deﬁ ned as improving func-
tional status and QALY. Multivariate analysis of variance, longitudinal logistic model, 
and multiple regressions were employed. Cost-effectiveness ratios per disability 
averted score and QALY gained were presented. A probabilistic sensitivity analysis 
was performed for uncertainty analysis. RESULTS: Compared to the control group, 
BI and QALY of patients with rehabilitation were signiﬁ cantly improved (P < 0.01). 
The incremental cost-effectiveness ratio of providing of rehabilitation services for 
stroke patients was 73,191 Baht per QALY. Cost-effectiveness acceptability curves 
ensure that the rehabilitation services are likely to represent good value for money at 
the ceiling ratio of 200,000 Baht per QALY. CONCLUSIONS: The rehabilitation 
services for disabled stroke survivors were cost effective under the Thai health-care 
setting. 
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